DrugCite
Search

INSULIN DETEMIR FLEXPEN

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Insulin Detemir Flexpen Adverse Events Reported to the FDA Over Time

How are Insulin Detemir Flexpen adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Insulin Detemir Flexpen, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Insulin Detemir Flexpen is flagged as the suspect drug causing the adverse event.

Most Common Insulin Detemir Flexpen Adverse Events Reported to the FDA

What are the most common Insulin Detemir Flexpen adverse events reported to the FDA?

Hypoglycaemia
48 (10.84%)
Hypoglycaemic Unconsciousness
18 (4.06%)
Pneumonia
16 (3.61%)
Dehydration
15 (3.39%)
Cerebral Haemorrhage
14 (3.16%)
Petit Mal Epilepsy
14 (3.16%)
Skull Fracture
14 (3.16%)
Confusional State
12 (2.71%)
Death
11 (2.48%)
Loss Of Consciousness
10 (2.26%)
Diabetic Ketoacidosis
9 (2.03%)
Show More Show More
Fall
8 (1.81%)
Tachycardia Paroxysmal
8 (1.81%)
Carbon Monoxide Diffusing Capacity ...
7 (1.58%)
Dyspnoea
7 (1.58%)
Intentional Overdose
7 (1.58%)
Acute Stress Disorder
6 (1.35%)
Asthma
6 (1.35%)
Carpal Tunnel Syndrome
6 (1.35%)
Hyperglycaemia
6 (1.35%)
Pancreatitis
6 (1.35%)
Total Lung Capacity Decreased
6 (1.35%)
Weight Decreased
6 (1.35%)
Convulsion
5 (1.13%)
Hip Fracture
5 (1.13%)
Myocardial Infarction
5 (1.13%)
Bladder Transitional Cell Carcinoma...
4 (.9%)
Bundle Branch Block Left
4 (.9%)
Cerebrovascular Accident
4 (.9%)
Dizziness
4 (.9%)
Food Allergy
4 (.9%)
Food Poisoning
4 (.9%)
Glycosylated Haemoglobin Increased
4 (.9%)
Hepatic Enzyme Increased
4 (.9%)
Hypertriglyceridaemia
4 (.9%)
Pancreatic Carcinoma
4 (.9%)
Pelvic Fracture
4 (.9%)
Abdominal Wall Abscess
3 (.68%)
Angioedema
3 (.68%)
Carotid Artery Stenosis
3 (.68%)
Cellulitis
3 (.68%)
Chronic Obstructive Pulmonary Disea...
3 (.68%)
Delirium
3 (.68%)
Diarrhoea
3 (.68%)
Hepatitis
3 (.68%)
Hypoglycaemic Coma
3 (.68%)
Intensive Care
3 (.68%)
Muscle Spasms
3 (.68%)
Pancreatic Mass
3 (.68%)
Premature Baby
3 (.68%)
Pulmonary Function Test Decreased
3 (.68%)
Abnormal Behaviour
2 (.45%)
Abscess
2 (.45%)
Blood Glucose Decreased
2 (.45%)
Blood Glucose Increased
2 (.45%)
Blood Pressure Decreased
2 (.45%)
Cardiac Failure Congestive
2 (.45%)
Congestive Cardiomyopathy
2 (.45%)
Decreased Appetite
2 (.45%)
Drug Exposure During Pregnancy
2 (.45%)
Electrocardiogram St Segment Abnorm...
2 (.45%)
Head Injury
2 (.45%)
Hypotension
2 (.45%)
Injection Site Abscess
2 (.45%)
Injection Site Erythema
2 (.45%)
Injection Site Pain
2 (.45%)
Radius Fracture
2 (.45%)
Renal Failure Chronic
2 (.45%)
Stress
2 (.45%)
Suicidal Ideation
2 (.45%)
Treatment Noncompliance
2 (.45%)
Umbilical Cord Vascular Disorder
2 (.45%)
Upper Limb Fracture
2 (.45%)
Viral Upper Respiratory Tract Infec...
2 (.45%)
Vomiting
2 (.45%)
Wrong Technique In Drug Usage Proce...
2 (.45%)
Alanine Aminotransferase Increased
1 (.23%)
Anorexia
1 (.23%)
Arteriosclerosis Coronary Artery
1 (.23%)
Aspartate Aminotransferase Increase...
1 (.23%)
Blood Alkaline Phosphatase Increase...
1 (.23%)
Blood Potassium Increased
1 (.23%)
Cellulitis Staphylococcal
1 (.23%)
Cerebral Infarction
1 (.23%)
Coronary Artery Occlusion
1 (.23%)
Diabetic Neuropathy
1 (.23%)
Fracture
1 (.23%)
Hyperhidrosis
1 (.23%)
Hypersensitivity
1 (.23%)
Hypoglycaemic Encephalopathy
1 (.23%)
Hypoglycaemic Seizure
1 (.23%)
Injection Site Cellulitis
1 (.23%)
Injection Site Infection
1 (.23%)
Mental Status Changes
1 (.23%)
Microalbuminuria
1 (.23%)
Mobility Decreased
1 (.23%)
Myocardial Ischaemia
1 (.23%)
Neuropathic Arthropathy
1 (.23%)
Pancreatic Carcinoma Metastatic
1 (.23%)
Panniculitis
1 (.23%)
Poor Personal Hygiene
1 (.23%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Insulin Detemir Flexpen, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Insulin Detemir Flexpen is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Insulin Detemir Flexpen

What are the most common Insulin Detemir Flexpen adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Insulin Detemir Flexpen, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Insulin Detemir Flexpen is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Insulin Detemir Flexpen According to Those Reporting Adverse Events

Why are people taking Insulin Detemir Flexpen, according to those reporting adverse events to the FDA?

Type 2 Diabetes Mellitus
47
Insulin-requiring Type Ii Diabetes ...
41
Type 1 Diabetes Mellitus
39
Insulin-requiring Type 2 Diabetes M...
38
Diabetes Mellitus Insulin-dependent
12
Diabetes Mellitus
3
Show More Show More
Diabetes Mellitus Non-insulin-depen...
1

Insulin Detemir Flexpen Case Reports

What Insulin Detemir Flexpen safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Insulin Detemir Flexpen. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Insulin Detemir Flexpen.